Dr. Yee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St
Yawkey 9A
Boston, MA 02114Phone+1 617-724-4000- Is this information wrong?
Summary
- Dr. Andrew J. Yee is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Massachusetts General Hospital and North Shore Medical Center. He is an Assistant Professor of Medicine at Harvard Medical School. He received his medical degree from Harvard Medical School and has been in practice 17 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2007
Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
Harvard Medical SchoolClass of 2000
Certifications & Licensure
NH State Medical License 2009 - 2025
MA State Medical License 2002 - 2024- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2012 May 01
- Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) Start of enrollment: 2013 Mar 01
Publications & Presentations
PubMed
- Successful Treatment of Posttransplant Monoclonal Gammopathy-associated C3 Glomerulopathy With Plasma Cell Clone-directed Therapy.Ayman Al Jurdi, Abraham Cohen Bucay, Leonardo V Riella, Andrew J Yee, Cherif Abdelmalek, Veronica Klepeis, Shoko Kimura, Kassem Safa> ;Transplantation Direct. 2024 May 1
- Quantification of Right Ventricular Amyloid Burden with 18F-florbetapir PET/CT and its Association with Right Ventricular Dysfunction and Outcomes in Light-Chain Amylo...Datar, Y., Clerc, O., Cuddy, S., Kim, S., Taylor, A., Neri, J., Benz, D., Bianchi, G., Yee, A., Sanchorawala, V., Ruberg, F., Landau, H., Liao, R., Kijewski, M., Jeros...> ;European Heart Journal. Cardiovascular Imaging. 2024 Jan 9
- 1 citationsRadiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy.Hazim S Ababneh, Andrew J Yee, Noopur S Raje, Sidney Martin, Matthew J Frigault, Andrea K Ng, Chirayu G Patel> ;Radiotherapy and Oncology. 2023 Dec 1
- Join now to see all
Lectures
- Analysis of Hospitalization and Readmissions after CAR T Cell Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Hospital Affiliations
Salem HospitalSalem, Massachusetts
Wentworth-Douglass HospitalDover, New Hampshire
Massachusetts General HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
